Kyntra Bio (KYNB) Net Margin (2014 - 2026)
Kyntra Bio (KYNB) posted Net Margin of 1.77% for Q1 2026, down 105.78% sequentially from 30.54% in Q4 2025, and down 78326.0% YoY from N/an in Q1 2025.
Kyntra Bio (KYNB) Net Margin (2014 - 2026) Analysis & Trends
Kyntra Bio has reported Net Margin for 13 years, with the latest figure at 1.77% in Q1 2026.
- Quarterly Net Margin fell 78326.0% year-over-year to 1.77% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2959.89% (up 122765.0% YoY) and the FY2025 annual result came in at 3752.42%, up 339619.0% from the prior year.
- Net Margin eased to 1.77% in Q1 2026 per KYNB's latest filing, from 30.54% in the prior quarter.
- Over five years, Net Margin peaked at 25372.36% in Q3 2024 and troughed at 4558.88% in Q1 2023.
- A 5-year average of 2852.72% and a median of 30.54% in 2025 frame the typical range for Net Margin.
- The sharpest annual moves came in 2024 and 2025: Net Margin jumped 2553255 bps in 2024, then sank 743671 bps in 2025.
- Over 5 years, Net Margin stood at 791.13% in 2022, then surged by 116 bps to 125.93% in 2023, then jumped by 575 bps to 849.98% in 2024, then slumped by 96 bps to 30.54% in 2025, then tumbled by 106 bps to 1.77% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 1.77%, 30.54%, and 19868.22% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.69 Bn | 130.84 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.29 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.79 Bn | 59.60 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 59.44 Bn | 54.31 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 30.92 Bn | 27.61 Bn | 992.69 Mn | 12.74% |
| 7 | BioNTech SE | 28.10 Bn | 9.71 Bn | 668.28 Mn | -16.51% |
| 8 | Insmed | 27.33 Bn | 26.17 Bn | 358.27 Mn | -3.12% |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 12.09% |
| 10 | Kyntra Bio | 29.63 Mn | 29.63 Mn | 1.47 Mn | 812.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.77% |
| Dec 31, 2025 | 30.54% |
| Sep 30, 2025 | 19,868.22% |
| Jun 30, 2025 | 451.04% |
| Mar 31, 2025 | 781.49% |
| Dec 31, 2024 | 849.98% |
| Sep 30, 2024 | 25,372.36% |
| Jun 30, 2024 | 7,887.75% |
| Mar 31, 2024 | 732.41% |
| Dec 31, 2023 | 125.93% |
| Sep 30, 2023 | -160.19% |
| Jun 30, 2023 | -612.71% |
| Mar 31, 2023 | -4,558.88% |
| Dec 31, 2022 | -791.13% |
| Sep 30, 2022 | -585.05% |
| Jun 30, 2022 | -245.55% |
| Mar 31, 2022 | -648.21% |
| Dec 31, 2021 | -812.56% |
| Sep 30, 2021 | 31.71% |
| Jun 30, 2021 | -552.25% |